Momenta Pharma (MNTA) 11.41 $MNTA
Healthcare Sector Equities Under Review - Nanosphere, SciClone Pharma, ConforMIS, and Momenta Pharma
PR Newswire - Thu Jun 30, 6:55AM CDT
On Wednesday, June 29, 2016, the NASDAQ Composite ended the trading session at 4,779.25, up 1.86%; the Dow Jones Industrial Average advanced 1.64%, to finish at 17,694.68; and the S&P 500 closed at 2,070.77, up 1.70%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), ConforMIS Inc. (NASDAQ: CFMS), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Learn more about these stocks by accessing their free trade alerts at:
CFMS: 7.64 (+0.23), SCLN: 13.48 (+0.27), MNTA: 11.41 (+0.20), NSPH: 1.69 (-0.01)
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016. Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015.
VCEL: 2.22 (+0.05), SCYX: 2.21 (+0.03), CFRX: 2.72 (-0.11), MNTA: 11.41 (+0.20), KERX: 7.25 (+0.35)
Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the dosing of the first healthy volunteers in a Phase 1 randomized, double-blind, placebo-controlled, ascending-dose cohort study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of M281, an anti-FcRn monoclonal antibody, for the treatment of autoimmune diseases.
MNTA: 11.41 (+0.20)
Shares of MNTA Up 26.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 1:03AM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on April 4th, 2016 at $9.55. In approximately 2 months, Momenta Pharmaceuticals has returned 26.91% as of today's recent price of $12.12.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA(R) (adalimumab) Biosimilar, at EULAR 2016
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company's lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
SHPG: 188.21 (-1.31), MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
GlobeNewswire - Sat Jun 04, 8:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented final data from the Phase 1 trial evaluating necuparanib in combination with nab-paclitaxel (nabP; Abraxane) and gemcitabine (gem) in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243) at the 2016 ASCO Annual Meeting, from 8:00 to 11:30 am CDT (Abstract #4117 / Poster #109) in Chicago, IL.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Shares Up 26.4% Since SmarTrend's Buy Recommendation (MNTA)
Comtex SmarTrend(R) - Wed Jun 01, 1:35PM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on April 4th, 2016 at $9.55. In approximately 2 months, Momenta Pharmaceuticals has returned 26.39% as of today's recent price of $12.07.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Wed May 25, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Goldman Sachs 37 Annual Healthcare Conference will be webcast on Wednesday, June 8 at 8 a.m. PT.
MNTA: 11.41 (+0.20)
Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.25 (-0.01), OGXI: 1.02 (+0.02), AMGN: 161.10 (+4.51), LLY: 79.66 (+0.34), BMY: 75.28 (+1.20), MNTA: 11.41 (+0.20), CELG: 105.03 (+0.62), EXEL: 8.15 (+0.01)
Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu May 19, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of its final results from the Phase 1 study of its drug candidate, necuparanib, in patients with metastatic pancreatic cancer. The poster will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
MNTA: 11.41 (+0.20)
Momenta (MNTA) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:20PM CDT
Momenta Pharmaceuticals Inc. (MNTA) reported a loss of 35 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 38 cents and the year-ago loss of 40 cents.
SHPG: 188.21 (-1.31), MYL: 44.54 (+0.84), BXLT: 46.02 (-0.18), MNTA: 11.41 (+0.20)
Momenta reports 1Q loss
Automated Insights - Tue May 03, 7:26AM CDT
CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Tuesday reported a loss of $24 million in its first quarter.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2016.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Announces Time Change for First Quarter 2016 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 26, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its first quarter 2016 earnings conference call and webcast. Momenta will now host its conference call and webcast at 9:00 a.m. EDT on Tuesday, May 3, 2016.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
GlobeNewswire - Mon Apr 25, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
DB: 12.97 (+0.37), MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Announces Date of First Quarter 2016 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2016 before the U.S. financial markets open on Tuesday, May 3, 2016.
MNTA: 11.41 (+0.20)
9 Things You Need to Know About Biosimilar Drugs
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 28, 1:59PM CDT
It's not often that investors get an opportunity to invest in a whole new class of drugs, but they've got an opportunity to invest on the ground floor with biosimilars. Last year, the Food and Drug Administration approved the first biosimilar drug, ...
BIIB: 251.30 (+4.03), MYL: 44.54 (+0.84), AMGN: 161.10 (+4.51), TEVA: 50.89 (+0.37), MNTA: 11.41 (+0.20), NVS: 82.13 (+0.33)
Should You Get Rid of Momenta Pharmaceuticals (MNTA) Now?
Zacks Equity Research - Zacks Investment Research - Mon Mar 14, 7:31AM CDT
Momenta Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ANIK: 53.30 (+0.94), MNTA: 11.41 (+0.20)
Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid
Arpita Dutt - Zacks Investment Research - Fri Mar 11, 8:37AM CST
Is the dream run for the biotech sector finally over?
GILD: 86.55 (+1.08), AMGN: 161.10 (+4.51), ABBV: 64.16 (+0.73), MNTA: 11.41 (+0.20), ARNA: 1.70 (+0.06), REGN: 378.35 (+6.90), CELG: 105.03 (+0.62)
Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 04, 4:19PM CST
What: Shares of Momenta Pharmaceuticals , a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P Global Market...
MNTA: 11.41 (+0.20)
Healthcare Sector Equities Under Review - Nanosphere, SciClone Pharma, ConforMIS, and Momenta Pharma
PR Newswire - Thu Jun 30, 6:55AM CDT
On Wednesday, June 29, 2016, the NASDAQ Composite ended the trading session at 4,779.25, up 1.86%; the Dow Jones Industrial Average advanced 1.64%, to finish at 17,694.68; and the S&P 500 closed at 2,070.77, up 1.70%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), ConforMIS Inc. (NASDAQ: CFMS), and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Learn more about these stocks by accessing their free trade alerts at:
CFMS: 7.64 (+0.23), SCLN: 13.48 (+0.27), MNTA: 11.41 (+0.20), NSPH: 1.69 (-0.01)
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
GlobeNewswire - Thu Jun 23, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016. Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015.
VCEL: 2.22 (+0.05), SCYX: 2.21 (+0.03), CFRX: 2.72 (-0.11), MNTA: 11.41 (+0.20), KERX: 7.25 (+0.35)
Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody
GlobeNewswire - Thu Jun 09, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the dosing of the first healthy volunteers in a Phase 1 randomized, double-blind, placebo-controlled, ascending-dose cohort study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of M281, an anti-FcRn monoclonal antibody, for the treatment of autoimmune diseases.
MNTA: 11.41 (+0.20)
Shares of MNTA Up 26.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 1:03AM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on April 4th, 2016 at $9.55. In approximately 2 months, Momenta Pharmaceuticals has returned 26.91% as of today's recent price of $12.12.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA(R) (adalimumab) Biosimilar, at EULAR 2016
GlobeNewswire - Wed Jun 08, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company's lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London.
SHPG: 188.21 (-1.31), MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
GlobeNewswire - Sat Jun 04, 8:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented final data from the Phase 1 trial evaluating necuparanib in combination with nab-paclitaxel (nabP; Abraxane) and gemcitabine (gem) in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243) at the 2016 ASCO Annual Meeting, from 8:00 to 11:30 am CDT (Abstract #4117 / Poster #109) in Chicago, IL.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Shares Up 26.4% Since SmarTrend's Buy Recommendation (MNTA)
Comtex SmarTrend(R) - Wed Jun 01, 1:35PM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on April 4th, 2016 at $9.55. In approximately 2 months, Momenta Pharmaceuticals has returned 26.39% as of today's recent price of $12.07.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th Annual Global Healthcare Conference
GlobeNewswire - Wed May 25, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Goldman Sachs 37 Annual Healthcare Conference will be webcast on Wednesday, June 8 at 8 a.m. PT.
MNTA: 11.41 (+0.20)
Rexahn's Drugs Deal a Death Blow to Solid Tumor Cancer
ACCESSWIRE - Thu May 19, 8:01AM CDT
Efficacy in Gemzar-resistant cancer is proven
RNN: 0.25 (-0.01), OGXI: 1.02 (+0.02), AMGN: 161.10 (+4.51), LLY: 79.66 (+0.34), BMY: 75.28 (+1.20), MNTA: 11.41 (+0.20), CELG: 105.03 (+0.62), EXEL: 8.15 (+0.01)
Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu May 19, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of its final results from the Phase 1 study of its drug candidate, necuparanib, in patients with metastatic pancreatic cancer. The poster will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.
MNTA: 11.41 (+0.20)
Momenta (MNTA) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:20PM CDT
Momenta Pharmaceuticals Inc. (MNTA) reported a loss of 35 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 38 cents and the year-ago loss of 40 cents.
SHPG: 188.21 (-1.31), MYL: 44.54 (+0.84), BXLT: 46.02 (-0.18), MNTA: 11.41 (+0.20)
Momenta reports 1Q loss
Automated Insights - Tue May 03, 7:26AM CDT
CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Tuesday reported a loss of $24 million in its first quarter.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2016.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Announces Time Change for First Quarter 2016 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 26, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its first quarter 2016 earnings conference call and webcast. Momenta will now host its conference call and webcast at 9:00 a.m. EDT on Tuesday, May 3, 2016.
MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
GlobeNewswire - Mon Apr 25, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
DB: 12.97 (+0.37), MNTA: 11.41 (+0.20)
Momenta Pharmaceuticals Announces Date of First Quarter 2016 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 19, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2016 before the U.S. financial markets open on Tuesday, May 3, 2016.
MNTA: 11.41 (+0.20)
9 Things You Need to Know About Biosimilar Drugs
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 28, 1:59PM CDT
It's not often that investors get an opportunity to invest in a whole new class of drugs, but they've got an opportunity to invest on the ground floor with biosimilars. Last year, the Food and Drug Administration approved the first biosimilar drug, ...
BIIB: 251.30 (+4.03), MYL: 44.54 (+0.84), AMGN: 161.10 (+4.51), TEVA: 50.89 (+0.37), MNTA: 11.41 (+0.20), NVS: 82.13 (+0.33)
Should You Get Rid of Momenta Pharmaceuticals (MNTA) Now?
Zacks Equity Research - Zacks Investment Research - Mon Mar 14, 7:31AM CDT
Momenta Pharmaceuticals has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off
ANIK: 53.30 (+0.94), MNTA: 11.41 (+0.20)
Biotech Investing Guide: 3 Stocks to Buy and 3 to Avoid
Arpita Dutt - Zacks Investment Research - Fri Mar 11, 8:37AM CST
Is the dream run for the biotech sector finally over?
GILD: 86.55 (+1.08), AMGN: 161.10 (+4.51), ABBV: 64.16 (+0.73), MNTA: 11.41 (+0.20), ARNA: 1.70 (+0.06), REGN: 378.35 (+6.90), CELG: 105.03 (+0.62)
Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 04, 4:19PM CST
What: Shares of Momenta Pharmaceuticals , a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P Global Market...
MNTA: 11.41 (+0.20)
